Original Research Article

Cancer frequency: Kars province

Yasemen Adali1*, Bülent Güvendi2, Hatice Beşeren3, Tuğba Toyran4, Gülname Fündik Güvendi5

1Department of Pathology, Çanakkale Onsekiz Mart University Medical Faculty, Çanakkale, Turkey
2Department of General Surgery, Rize Recep Tayyip Erdoğan University Medical Rize, Turkey
3Department of Pathology, Kafkas Veterinary Medicine Faculty, Kars, Turkey
4Department of Pathology, Adana State Hospital, Adana, Turkey
5Department of Pathology, Rize Recep Tayyip Erdoğan University Medical Rize, Turkey

Received: 23 February 2019
Accepted: 11 March 2019

*Correspondence:
Dr. Yasemen Adali,
E-mail: yasemenadali@hotmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Malignant tumors are important causes of mortality and morbidity in the world. It is known that the incidence of tumors- in which a large number of etiologic agents are identified and continued to be investigated- varies according to age, gender and geographical location. This study aimed to determine the prevalence and localization distributions of malignant tumors in Kars.

Methods: The study included 17012 patients whose biopsy materials were evaluated in the Department of Pathology of Kafkas University Health Research and Practice Hospital between 2014-2017.

Results: The mean age of all cancer cases was 63.3±14.8 and the median age was 63. The cancer frequency was detected 22.6% in 2014, 23.3% in 2015, 26.9% in 2016 and 27.2% in 2017 with general slight male dominance.

Conclusions: The incidence of cancer in our country is found to be lower compared to the world data. It is necessary to examine and take into account the regional and city-based cancer statistics that serve as an important key stone in the planning of health policies and health investments in our country. Regional data is not only important for treatment services, but also for preventive health services and early diagnosis.

Keywords: Cancer, Frequency, Kars, Statistics, Tumor

INTRODUCTION

Malignant tumors are important causes of mortality and morbidity in the world. These tumors are the leading causes of death in developed countries and they are the second most common cause deaths after cardiac diseases in developing countries.1 The incidence of tumors in which a large number of etiologic agents are identified and continued to be investigated, varies according to age, gender and geographical location. These differences in the world stand out among the countries and even cities. Turkey is located in West Asia region when the world is divided into 22 regions based on cancer frequency and mortality rates considering the geographical characteristics and living conditions.2 Despite the increase in cancer registry comprehensibility in our country, there are still shortcomings in the reports even though the rates are more accurate compared to previous years. It is important to determine the frequency of cancer for many reasons, especially for the mortality, morbidity, reduction of quality of life, negative effects on personal and national economy. Assessment of overall cancer incidence in Turkey, it is reported to be 221.5 per hundred thousands, and most frequent cancer seen among women is breast and lung among men.3 When the studies conducted in different cities within the country are...
evaluated: İzmir and Konya showed similar results to overall Turkey's data with highest rates of breast cancer among women and lung among men.4,5 In a study conducted in Van, the most common cancer among women is reported to as esophagus and prostate cancer among men, and in Corum, the most common cancer among both men and women has been reported as skin cancer.6,7 In this present study, it was aimed to determine the prevalence, age, sex and localization distributions of malignant tumors in Kars, which is one of border cities in Eastern Anatolia region.

METHODS

The study included 17012 patients whose biopsy materials were evaluated in the Department of Pathology of Kafkas University Health Research and Practice Hospital between 2014-2017. Cases with suspected diagnosis and cases with only cytology material were excluded from the study. Frequency analyzes and statistical evaluations of the data obtained by scanning the pathology reports in the hospital information management system were performed with SPSS 15.0 package program. Patients with tumor recurrence were evaluated with the first biopsy diagnoses. Incisional and excisional biopsy reports were evaluated together for final data analysis in cases who have both. Gender, age, organ and system distributions of 663 cases diagnosed with cancer were determined.

RESULTS

The mean age of all cancer cases was 63.3±14.8 and the median age was 63. The mean age of the cases in 2014 was 65.5±13.4, in 2015: 63.4±16.9, in 2016: 60.9±15.9 and in 2017: 63.8±12.8. When the age distribution of the cases was analyzed according to years, it was observed that the mean of 2014 was statistically higher than that of 2016 (p = 0.011), but there was no difference between the other years (p>0.05). Of all the cases, 291 (43.9%) were female and 372 (56.1%) were male. When the general tumor frequency was evaluated with chi-square test between male and female cases, it was found that the frequency of tumors in male cases was statistically higher than female cases (p=0.002).

Table 1: Distribution of cancer cases by years and the cancer frequency in women and men.

| Year | Number of biopsies (N/%) | General (N/%) | Women (N/%) | Men (N/%) |
|------|-------------------------|--------------|-------------|-----------|
| 2014 | 3851 (22.6)             | 206 (31.1)   | 69 (33.5)   | 137 (66.5) |
| 2015 | 3958 (23.3)             | 138 (20.8)   | 54 (39.1)   | 84 (60.9)  |
| 2016 | 4582 (26.9)             | 167 (25.2)   | 84 (53.3)   | 83 (49.7)  |
| 2017 | 4621 (27.2)             | 152 (22.9)   | 84 (55.3)   | 68 (44.7)  |
| Total| 17012 (100)             | 663 (100)    | 291 (43.9)  | 372 (56.1) |

Table 2: General and yearly distribution of cancer cases by organ.

| Localization (organ) | General (N/%) | 2014 (N/%) | 2015 (N/%) | 2016 (N/%) | 2017 (N/%) |
|----------------------|--------------|------------|------------|------------|------------|
| Stomach              | 95 (14.3)    | 10 (19.4)  | 17 (12.3)  | 17 (10.2)  | 21 (13.8)  |
| Colorectum           | 86 (13.0)    | 27 (13.1)  | 15 (10.9)  | 24 (14.4)  | 20 (13.2)  |
| Esophagus            | 22 (3.3)     | 9 (4.4)    | 4 (2.9)    | 4 (2.4)    | 5 (3.3)    |
| Skin                 | 75 (11.3)    | 28 (13.6)  | 18 (13.0)  | 11 (6.6)   | 18 (11.8)  |
| Soft tissue          | 5 (0.8)      | 1 (0.5)    | 3 (2.2)    | 0 (0)      | 1 (0.7)    |
| Prostate             | 79 (11.9)    | 28 (13.6)  | 13 (9.4)   | 21 (12.6)  | 17 (11.2)  |
| Urinary bladder      | 55 (8.3)     | 17 (8.3)   | 14 (10.1)  | 12 (7.2)   | 12 (7.9)   |
| Breast               | 80 (12.1)    | 8 (3.9)    | 14 (10.1)  | 38 (22.8)  | 20 (13.2)  |
| Thyroid              | 92 (13.9)    | 29 (14.1)  | 19 (13.8)  | 26 (15.6)  | 18 (11.8)  |
| Kidney               | 9 (1.4)      | 1 (0.5)    | 4 (2.9)    | 3 (1.8)    | 1 (0.7)    |
| Nasopharynx          | 3 (0.5)      | 3 (1.5)    | 1 (0.7)    | 1 (0.6)    | 0 (0)      |
| Lymphoid             | 8 (1.2)      | 2 (1.0)    | 3 (2.2)    | 1 (0.6)    | 1 (0.7)    |
| Brain                | 4 (0.6)      | 3 (1.5)    | 2 (%1.4)   | 0 (0)      | 0 (0)      |
| Bone                 | 4 (0.6)      | 4 (1.9)    | 1 (0.7)    | 0 (0)      | 0 (0)      |
| Lung                 | 8 (1.2)      | 1 (0.5)    | 3 (2.2)    | 1 (0.6)    | 0 (0)      |
| Endometrium          | 19 (2.9)     | 3 (1.5)    | 2 (1.4)    | 3 (1.8)    | 13 (8.6)   |
| Uterine cervix       | 4 (0.6)      | 1 (0.5)    | 0 (0)      | 1 (0.6)    | 0 (0)      |
| Salivary gland       | 5 (0.8)      | 1 (0.5)    | 1 (0.7)    | 1 (0.6)    | 2 (1.3)    |
| Ovary                | 5 (0.8)      | 0 (0)      | 1 (0.7)    | 1 (0.6)    | 3 (2.0)    |
| Larynx               | 2 (0.3)      | 0 (0)      | 2 (1.4)    | 0 (0)      | 0 (0)      |
| Gallbladder          | 1 (0.1)      | 0 (0)      | 1 (0.7)    | 0 (0)      | 0 (0)      |
| Testis               | 1 (0.1)      | 0 (0)      | 0 (0)      | 1 (0.6)    | 0 (0)      |
| Adrenal              | 1 (0.1)      | 0 (0)      | 0 (0)      | 1 (0.6)    | 0 (0)      |
| Total                | 663 (100)    | 206 (100)  | 138 (100)  | 167 (100)  | 152 (100)  |
### Table 3: General and yearly distribution of cancer cases by system.

| Localization (System) | General (N/%) | 2014 (N/%) | 2015 (N/%) | 2016 (N/%) | 2017 (N/%) |
|-----------------------|--------------|------------|------------|------------|------------|
| Gastrointestinal      | 204 (30.8)   | 76 (36.9)  | 37 (26.8)  | 45 (26.9)  | 46 (30.3)  |
| Urogenital            | 144 (21.7)   | 46 (22.3)  | 31 (22.5)  | 37 (22.2)  | 30 (19.7)  |
| Head-neck             | 10 (1.5)     | 2 (1.0)    | 4 (2.9)    | 2 (1.2)    | 2 (1.3)    |
| Skin                  | 75 (11.3)    | 28 (13.6)  | 18 (13.0)  | 11 (6.6)   | 18 (11.8)  |
| Soft tissue-bone      | 9 (1.4)      | 4 (1.9)    | 4 (2.9)    | 0 (0)      | 1 (7)      |
| Female genital        | 28 (4.2)     | 4 (1.9)    | 3 (2.2)    | 5 (3.0)    | 16 (10.5)  |
| Lymphoid              | 8 (1.2)      | 3 (1.5)    | 3 (2.2)    | 1 (0.6)    | 1 (0.7)    |
| Breast                | 80 (12.1)    | 8 (3.9)    | 14 (10.1)  | 38 (22.8)  | 20 (13.2)  |
| Endocrine             | 93 (14.0)    | 29 (14.1)  | 19 (13.8)  | 27 (16.2)  | 18 (11.8)  |
| Lung                  | 8 (1.2)      | 4 (1.9)    | 3 (2.2)    | 1 (0.6)    | 0 (0)      |
| Brain                 | 4 (0.6)      | 2 (1.0)    | 2 (1.4)    | 0 (0)      | 0 (0)      |
| **Total**             | **663 (100.0)** | **206 (100)** | **138 (100.0)** | **167 (100)** | **152 (100)** |

### Table 4: General and yearly distribution of cancer cases by organ in women.

| Localization (organ)       | General (N/%) | 2014 (N/%) | 2015 (N/%) | 2016 (N/%) | 2017 (N/%) |
|----------------------------|---------------|------------|------------|------------|------------|
| Stomach                    | 27(9.3)       | 9 (13.0)   | 3 (5.6)    | 3 (3.6)    | 12 (14.3)  |
| Colorectum                 | 40 (13.7)     | 13 (18.8)  | 6 (11.1)   | 11 (13.1)  | 10 (11.9)  |
| Eosophagus                 | 7 (2.4)       | 2 (2.9)    | 2 (3.7)    | 1 (1.2)    | 2 (2.4)    |
| Skin                       | 23 (7.9)      | 7 (10.1)   | 7 (13.0)   | 4 (4.8)    | 5 (6.0)    |
| Soft tissue                | 0 (0.7)       | 0 (0)      | 2 (3.7)    | 0 (0)      | 0 (0)      |
| Urinary bladder            | 8 (2.7)       | 1 (1.4)    | 0 (0)      | 2 (2.4)    | 5 (6.0)    |
| Breast                     | 77 (26.5)     | 8 (11.6)   | 12 (22.2)  | 38 (45.2)  | 19 (22.6)  |
| Thyroid                    | 68 (23.4)     | 21 (30.4)  | 14 (25.9)  | 19 (22.6)  | 14 (16.7)  |
| Kidney                     | 3 (1.0)       | 1 (1.4)    | 2 (3.7)    | 0 (0)      | 0 (0)      |
| Lymphoid                   | 3 (1.0)       | 1 (1.4)    | 2 (3.7)    | 0 (0)      | 0 (0)      |
| Brain                      | 1 (0.3)       | 1 (1.4)    | 0 (0)      | 0 (0)      | 0 (0)      |
| Bone                       | 1 (0.3)       | 1 (1.4)    | 0 (0)      | 0 (0)      | 0 (0)      |
| Lung                       | 1 (0.3)       | 0 (0)      | 0 (0)      | 1 (1.2)    | 0 (0)      |
| Endometrium                | 19 (6.6)      | 1 (1.4)    | 2 (3.7)    | 3 (3.6)    | 13 (15.5)  |
| Uterine Cervix             | 3 (1.0)       | 2 (2.9)    | 0 (0)      | 1 (1.2)    | 0 (0)      |
| Salivary gland             | 2 (0.7)       | 1 (1.4)    | 0 (0)      | 0 (0)      | 1 (1.2)    |
| Ovary                      | 5 (1.7)       | 0 (0)      | 1 (1.9)    | 1 (1.2)    | 3 (3.6)    |
| Gallbladder                | 1 (0.3)       | 0 (0)      | 1 (1.9)    | 0 (0)      | 0 (0)      |
| Adrenal                    | 1 (0.3)       | 0 (0)      | 0 (0)      | 0 (0)      | 0 (0)      |
| **Total**                  | **291 (100)** | **69 (100)** | **54 (100)** | **84 (100)** | **84 (100)** |

### Table 5: General and yearly distribution of cancer cases by system in women.

| Localization (System)      | General (N/%) | 2014 (N/%) | 2015 (N/%) | 2016 (N/%) | 2017 (N/%) |
|----------------------------|--------------|------------|------------|------------|------------|
| Gastrointestinal           | 75 (25.8)    | 24 (34.8)  | 12 (22.2)  | 15 (17.9)  | 24 (28.6)  |
| Urogenital                 | 11 (3.8)     | 2 (2.9)    | 2 (3.7)    | 2 (2.4)    | 5 (6)      |
| Head-neck                  | 2 (0.7)      | 1 (1.4)    | 0 (0)      | 0 (0)      | 1 (1.2)    |
| Skin                       | 23 (7.9)     | 7 (10.1)   | 7 (13.0)   | 4 (4.8)    | 5 (6.0)    |
| Soft tissue-bone           | 3 (1.0)      | 1 (1.4)    | 2 (3.7)    | 0 (0)      | 0 (0)      |
| Female genital             | 27 (9.3)     | 3 (4.3)    | 3 (5.6)    | 5 (6.0)    | 16 (19.0)  |
| Lymphoid                   | 3 (1.0)      | 1 (1.4)    | 2 (3.7)    | 0 (0)      | 0 (0)      |
| Breast                     | 77 (26.5)    | 8 (11.6)   | 12 (22.2)  | 38 (45.2)  | 19 (22.6)  |
| Endocrine                  | 68 (23.4)    | 21 (30.4)  | 14 (25.9)  | 19 (22.5)  | 14 (16.7)  |
| Lung                       | 1 (0.3)      | 0 (0)      | 0 (0)      | 1 (1.2)    | 0 (0)      |
| Brain                      | 1 (0.3)      | 1 (1.4)    | 0 (0)      | 0 (0)      | 0 (0)      |
| **Total**                  | **291 (100)** | **69 (100)** | **54 (100)** | **84 (100)** | **84 (100)** |
Table 6: General and yearly distribution of cancer cases by organ in men.

| Localization (organ) | General (N/%) | 2014 (N/%) | 2015 (N/%) | 2016 (N/%) | 2017 (N/%) |
|----------------------|--------------|------------|------------|------------|------------|
| Stomach              | 68 (18.3)    | 31 (22.6)  | 14 (16.7)  | 14 (16.9)  | 9 (13.0)   |
| Colorectum           | 46 (12.4)    | 14 (10.2)  | 9 (10.7)   | 13 (15.7)  | 10 (14.5)  |
| Esophagus            | 15 (4.0)     | 7 (5.1)    | 2 (2.4)    | 3 (3.6)    | 3 (4.3)    |
| Skin                 | 52 (14.0)    | 21 (15.3)  | 11 (13.1)  | 7 (8.4)    | 14 (20.3)  |
| Soft tissue          | 3 (0.8)      | 1 (0.7)    | 1 (1.2)    | 0 (0)      | 1 (1.4)    |
| Prostate             | 79 (21.2)    | 28 (20.4)  | 13 (15.5)  | 21 (25.3)  | 17 (24.6)  |
| Urinary bladder      | 47 (12.6)    | 16 (11.7)  | 14 (16.7)  | 10 (12.0)  | 7 (10.1)   |
| Breast               | 3 (0.8)      | 0 (0)      | 2 (2.4)    | 0 (0)      | 1 (1.4)    |
| Thyroid              | 24 (6.5)     | 8 (5.8)    | 5 (6.0)    | 7 (8.4)    | 4 (5.8)    |
| Kidney               | 6 (1.6)      | 0 (0)      | 2 (2.4)    | 3 (3.6)    | 1 (1.4)    |
| Nasopharynx          | 3 (0.8)      | 1 (0.7)    | 1 (1.2)    | 1 (1.2)    | 0 (0)      |
| Lymphoid             | 5 (1.3)      | 2 (1.5)    | 1 (1.2)    | 1 (1.2)    | 1 (1.4)    |
| Brain                | 3 (0.8)      | 1 (0.7)    | 2 (2.4)    | 0 (0)      | 0 (0)      |
| Bone                 | 3 (0.8)      | 2 (1.5)    | 1 (1.2)    | 0 (0)      | 0 (0)      |
| Lung                 | 7 (1.9)      | 4 (2.9)    | 3 (3.6)    | 0 (0)      | 0 (0)      |
| Salivary gland       | 3 (0.8)      | 0 (0)      | 1 (1.2)    | 1 (1.2)    | 1 (1.4)    |
| Larynx               | 2 (0.5)      | 0 (0)      | 2 (2.4)    | 0 (0)      | 0 (0)      |
| Testis               | 1 (0.3)      | 0 (0)      | 0 (0)      | 1 (1.2)    | 0 (0)      |
| Adrenal              | 1 (0.3)      | 0 (0)      | 0 (0)      | 1 (1.2)    | 0 (0)      |
| Total                | 372 (100)    | 137 (100)  | 84 (100)   | 83 (100)   | 68 (100)   |

Table 7: General and yearly distribution of cancer cases by system in men.

| Localization (System) | General (N/%) | 2014 (N/%) | 2015 (N/%) | 2016 (N/%) | 2017 (N/%) |
|----------------------|--------------|------------|------------|------------|------------|
| Gastrointestinal     | 129 (34.7)   | 52 (38.0)  | 25 (29.8)  | 30 (36.1)  | 22 (31.9)  |
| Urogenital           | 133 (35.8)   | 44 (32.1)  | 29 (34.5)  | 35 (42.2)  | 25 (36.2)  |
| Head-neck            | 8 (2.2)      | 1 (0.7)    | 4 (4.8)    | 2 (2.4)    | 1 (1.4)    |
| Skin                 | 52 (14.0)    | 21 (15.3)  | 11 (13.1)  | 7 (8.4)    | 14 (20.3)  |
| Soft tissue-bone     | 6 (1.6)      | 3 (2.2)    | 2 (2.4)    | 0 (0)      | 1 (1.4)    |
| Lymphohid            | 5 (0.3)      | 2 (1.5)    | 1 (1.2)    | 1 (1.2)    | 1 (1.4)    |
| Breast               | 3 (1.3)      | 0 (0)      | 2 (2.4)    | 0 (0)      | 1 (1.4)    |
| Endocrine            | 25 (6.7)     | 8 (5.8)    | 5 (6.0)    | 8 (9.6)    | 4 (5.8)    |
| Lung                 | 7 (1.9)      | 4 (2.9)    | 3 (3.6)    | 0 (0)      | 0 (0)      |
| Brain                | 3 (0.8)      | 1 (0.7)    | 2 (2.4)    | 0 (0)      | 0 (0)      |
| Total                | 372 (100)    | 137 (100)  | 84 (100)   | 83 (100)   | 68 (100)   |

The distribution of cancer cases by years and their frequency in females are presented in Table 1. According to the statistics done by Mann Whitney U test for years, it was found that cancer cases were statistically higher in 2014 than in 2015, 2016 and 2017 (p values were 0.000, 0.043, 0.004, respectively). No significant difference was observed between the other years (p>0.05).

The distribution of all cancer cases according to the general and yearly based on organ is given in Table 2 and the distribution of based on system is given in Table 3.

The mean age of the women cases was 58.9±15.2 and the median age was 5 years. The mean age of women in the year 2014 was 60.4±14.9, 2015 was 57.2±18.1, 2016 was 55.6±15.3, and in 2017 it was 62.1±12.5. Table 4 shows the general and yearly distribution in terms of organ and Table 5 shows distribution according to organ basis in women.

The mean age of men was 66.7±13.5 and median was 68 years. The mean age of the year 2014 was 68.0±11.9, 2015 was 65.7±15.3, 2016 was 66.3±14.7, and 2017 was 66.1±13.1. Table 6 shows the general and yearly distribution in terms of organ and Table 7 shows distribution according to organ basis in men.

**DISCUSSION**

There are 25 million cancer cases and 12.4 million new cases of cancer in the world according to the World Health Organisation's (WHO) 2010 data. It is known that...
cancer incidence is increasing all over the world. The main reason for this situation is the increase in diagnostic facilities and increase in the access to the diagnostic facilities. Likewise, cancer survival is also increased due to the advance in diagnostic facilities as well as treatment options and success of treatment. In Turkey in 2013, according to Ministry of Health statistics, cancer incidence is reported as 281.6 per 100000.\(^9\) Table 8 shows five most frequent tumors detected in our study and other study's results conducted in different provinces of Turkey. As it is understood from the Table 8, the different sequence of tumor frequencies in different cities suggests that many factors effect tumor diversity. One of them is socioeconomic status and cultural differences. The probable cause of the higher incidence of breast cancers in women in Istanbul may be considered as socio-culturally the cosmopolitan structure of Istanbul and the relative altitude at the level of education. Another important reason is the effect of climatic factors which is realted to skin carcinomas as it is observed in Hatay.

| City     | 1          | 2          | 3          | 4          | 5          |
|----------|------------|------------|------------|------------|------------|
| Kars\(^*\) | Stomach    | Thyroid    | Colorectum | Breast     | Prostate   |
| Konya\(^4\) | Lung       | Stomach    | CNS\(^*\)  | Hematologic | Colon      |
| Çorum\(^3\)  | Skin       | Prostate   | Stomach    | Urinary bladder | Breast     |
| Van\(^1\)   | Stomach    | Eosophagus | Breast     | Colorectum | Lung       |
| Istanbul\(^11\) | Breast   | Colorectum | Stomach    | Lung       | Prostate   |
| Hatay\(^12\) | Skin       | Breast     | Urinary bladder | Colorectum | Prostate   |
| Şırnak\(^13\) | Skin       | Thyroid    | Colorectum | Breast     | Stomach    |

Similar to our study, Van is another city where stomach cancers are common, and is also one of the cities where cold winter months pass due to geographical location and hot drinks are consumed at high frequency and high temperature. In a study evaluating gastric endoscopic biopsies performed in Kars province, the presence of *Helicobacter pylori* (Hp) was detected in 72.1% of biopsies.\(^14\) Therefore, we suggest that the incidence of high Hp also plays a role in the etiopathogenesis of stomach cancers which is most common cancer in Kars.

When world-wide data are analyzed, the most common cancers in women can be counted as breast, colorectal, uterine cervix; and in men, lung, prostate and colorectal.\(^15\) According to US data of 2012, the 3 most common tumors in women were breast, lung, colorectal carcinomas; and in men prostate, lung colorectal carcinomas.\(^15\) A study in year 2000 revealed that head and neck cancers were the first in both women and men, while colon cancer was the second in both sexes in France.\(^16\) Breast cancer in women and lung cancer in men has been reported in third place in the same study. According to 2013 data from Turkey, breast, thyroid and colorectal carcinomas are the most common cancers in women and lung, prostate and bladder cancers in men.\(^9\)

| City     | Women 1 | Men 1 | Women 2 | Men 2 | Women 3 | Men 3 |
|----------|---------|------|---------|------|---------|------|
| Kars\(^*\) | Breast  | Prostate | Thyroid | Stomach | Colon | Skin |
| İzmir\(^4\) | Breast  | Lung    | Skin    | Stomach | Endometrium | Larynx |
| Konya\(^4\) | Breast  | Lung    | CNS\(^*\) | Stomach | Hematological | Hematological |
| Van\(^6\) | Eosophagus | Prostate | Stomach | Skin    | Skin    | Lung |
| Çorum\(^3\) | Skin    | Skin    | Breast  | Prostate | Thyroid | Urinary bladder |
| Istanbul\(^11\) | Breast  | Colorectum | Colorectum | Lung | Gynecological | Stomach |
| Hatay\(^12\) | Skin    | Skin    | Thyroid | Colorectum | Breast   | Stomach |
| Eskişehir\(^17\) | Breast  | Skin    | Skin    | Larynx   | Colorectum | Lung |
| Sivas\(^18\) | Skin    | Skin    | Breast  | Urinary bladder | Endometrium | Prostate |
| Şanlıurfa\(^19\) | Breast  | Urinary bladder | Stomach | Lung | Thyroid | Larynx |
| Diyarbakır\(^20\) | Skin    | Skin    | Breast  | Lymphoid | Lymphoid | Lung |
Table 9 shows the most common cancer types among women and men of our study and various studies from different cities of Turkey. When the data of the table are evaluated, even there are differences between the cities in male and female patients similar to general cancer frequencies; breast cancers are the most common cancers in women in most cities. As in the general cancer data, one other similarity observed between Van and Kars is that the most common male cancer is prostate cancer. Although thyroid lesions are more common in women in general, it is not considered to be a coincidence that the second most common type of cancer in Kars is thyroid. Kars is located on the border with Armenia due to its geographical location. The “Metsamor” nuclear power plant is still working and it is one of the oldest nuclear power plants in the world. This nuclear power plant does not have a protection basin to protect nuclear fuel in the same way as the nuclear power plant in Chernobyl. Therefore, high frequency thyroid cancers detected in Kars are thought to be associated with radiation. Gastric cancers in men are thought to be associated with hot drink consumption and Hp as in general tumor incidence.

It is thought that fiber-poor nutrition may play a role in the etiology of colorectal carcinomas which are observed in women in the third place. Another study in Kars also revealed the relative high incidence (10.4%) in colorectal carcinoma in women while evaluating the colonscopic biopsy results. Basal cell carcinoma and squamous cell carcinoma constitute the majority of skin cancers in men which takes the third place in men in Kars. This situation can be explained by the sun exposure of the local people engaged in animal husbandry.

Since 1982, cancer is one of the mandatory diseases in our country. In Turkey in 2013, according to Ministry of Health statistics, cancer incidence is reported as 281.6 per 100000. The incidence of cancer in our country is found to be lower compared to the world data, however it is doubtful whether this decrease represents a reality or not. Although the cancer registry system was first established in 1992, it is known that there are still some deficiencies and limitations in the notification of the cases. It can be argued that this situation is caused by the rural populations and inadequacy of medical controls as well as the inability of the registry system to be active due to the inadequate application of patients in primary health care institutions.

**CONCLUSION**

It is necessary to examine and take into account the regional and city-based cancer statistics that serve as an important key stone in the planning of health policies and health investments in our country. Regional data is not only important for treatment services, but also for preventive health services and early diagnosis. In this context, it is thought that the publications which include the annual city based data from all cities should be increased in Turkey as well as the whole world.

This study has several limitations. The study data were collected from Health Research and Application Hospital in Kars between 2014-2017. The fact that the State Hospital data could not be included is an important limitation of the study. Between 2014-2017 some departments such as pulmonary diseases department did not actively served time to time. Moreover the lack of treatment facilities for leukemia/lymphoma and brain tumors lead patient's attendance to larger health centers for diagnosis. These and similar conditions cause false negativities in the proportion of related tumors

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** The study was approved by the Institutional Ethics Committee

**REFERENCES**

1. Mathers C, Fat DM, Boerma JT. The global burden of disease: 2004 update. Geneva, Switzerland: World Health Organization; 2008.

2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA Cancer J Clin. 2011;61:69-90.

3. Gültekin M, Boztaş G. Türkiye kanser istatistikleri 2014. Available at: https://hsigm saglik.gov.tr/depobirimler/kanserdh/istatistik/2009kanseraporanu-1.pdf.

4. Fidaner D, Eser SY, Parkin DM. Incidence in İzmir in 1993-1994: First results from İzmir Cancer Registry. Eur J Cancer. 2001;37:83-97.

5. Eczirli Ş, Borazan A, Tek B, Deveci A, Polat H. The determination of adult cancer cases among the patients admitted to the education and investigation hospital, faculty of medicine, university of selçuk of the between 1993 and 1999 years. T Klin J Med Sci. 2002;22:349-53.

6. Uğraş S, Dilek H, Akman E, Akpolat N, Karakök M. Yüzüncü yıl Üniversitesi Tıp Fakültesi Patoloji Anabilim Dah'ında tanı konan kanserlerin sıklığı ve dağılımı. Van Tıp Derg. 1996;3:148-54.

7. Baş Y, Uzbay P, Güney G, Erenler BH, Yılmaz D, Özdemir Ç. A Study on distribution of cancer cases diagnosed in corum. Turkish J Pathol. 2014;30:118-23.

8. Ferlay J, Shin, HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC Cancer Base No. 10. Lyon International Agency for Research on Cancer; 2010:29.

9. TC Sağlık Bakanlığı Sağlık İstatistikleri Yılığı, 2012. Available at: http://www.saglik.gov.tr/TR/dosya/1-87578/h/istaturk2012.pdf.
10. Alıcı S, İzmirli M, Doğan E. Epidemiologic evaluation of the patients admitted to Department of Medical Oncology, Yüzüncü Yıl University, Medical Faculty. Türk Onkoloji Dergisi. 2006;21(2):87-97.
11. Gürsu RU, Kesmez Acar Ö, Karaçetin D, Mermut Ö, Ökten B, Güner Ş. İstanbul Research and Training Hospital Oncology Division: 18-Month Results of a Newly Formed Unit. Istanbul Med J. 2012;13(1):13-8.
12. Arıca S, Nazlıcan E, Özer C, Benk Şilfeler D, Arıca V, Özgür T, Özaydın Ü. The frequency and distribution of cancer cases in the Hatay District in 2008. J Clin Exp Invest. 2011;2(2):192-5.
13. Bozkurt K, Sert Bektas S, Doğru N. Cancer Statistics of Şırnak City. Turkish J Pathol. 2011;27(3):230-4.
14. Adali Y, Eroğlu HA, Fındık Güvendi G. Endoscopic Gastric Biopsy Results: Kars Province. Kafkas J Med Sci. 2017;7(1):47-52.
15. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Center Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr.
16. Colonna M, Hedelin G, Esteve J, Grosclaude P, Launoy G, Buemi A, et al. National cancer prevalence estimation in France. Int J Cancer. 2000 Jul 15;87(2):301-4.
17. Dündar E, Öner Ü, İşılşoy S, Tel N, Kabukçuoğlu S. Eskişehir il'inde 1992-1995 yılları arasında görülen kanser olgularının değerlendirilmesi. Türk Ekopatol Derg. 1998;4(3-4):101-6.
18. Eğilmez R, Düzcan E. Cumhuriyet Üniversitesi Tip Fakültesi Patoloji Anabilim Dalı’nda kanser sıklığı üzerine bir çalışma. Türk Neopl Derg. 1992;1(2):37-42.
19. Bitiren M, Öznardal İ, Baba F, Nazlıgül Y, Eraslan H. The evaluation of cancer cases in Şanlıurfa province (1995-2002) Türkiye Ekopatoloji Dergisi. 2003;9(1-2):11-6.
20. Özêncî S. Patoloji Arşivindeki 10 yıllık kanser (1991-2000) olgularının genel değerlendirilmesi. Dicle Tip Dergisi. 2007;34:164-9.
21. Güvendi GF, Eroğlu HA, Adali Y. Kars Yöresi Alt Gastrointestinal Endoskopik Biyopsi Sonuçları. Kafkas Tip Bilimleri Dergisi.;8(1):70-9.

Cite this article as: Adali Y, Güvendi B, Beşeren H, Toyran T, Güvendi GF. Cancer frequency: Kars province. Int J Res Med Sci 2019;7:1067-73.